WallStSmart

Cigna Corp (CI)vsClover Health Investments Corp (CLOV)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Cigna Corp generates 14192% more annual revenue ($274.90B vs $1.92B). CI leads profitability with a 2.2% profit margin vs -4.5%. CI earns a higher WallStSmart Score of 63/100 (C+).

CI

Buy

63

out of 100

Grade: C+

Growth: 5.3Profit: 5.5Value: 7.3Quality: 4.8
Piotroski: 2/9

CLOV

Hold

36

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 4.3
Piotroski: 2/9Altman Z: -1.36
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CISignificantly Overvalued (-79.3%)

Margin of Safety

-79.3%

Fair Value

$150.76

Current Price

$270.36

$119.60 premium

UndervaluedFair: $150.76Overvalued

Intrinsic value data unavailable for CLOV.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CI5 strengths · Avg: 8.6/10
P/E RatioValuation
12.0x10/10

Attractively priced relative to earnings

Market CapQuality
$71.02B9/10

Large-cap with strong market position

PEG RatioValuation
0.768/10

Growing faster than its price suggests

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$5.83B8/10

Generating 5.8B in free cash flow

CLOV1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
44.7%10/10

Revenue surging 44.7% year-over-year

Areas to Watch

CI4 concerns · Avg: 2.8/10
Profit MarginProfitability
2.2%3/10

2.2% margin — thin

Operating MarginProfitability
3.5%3/10

Operating margin of 3.5%

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-9.3%2/10

Earnings declined 9.3%

CLOV4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$954.89M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-26.3%2/10

ROE of -26.3% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : CI

The strongest argument for CI centers on P/E Ratio, Market Cap, PEG Ratio. Revenue growth of 10.4% demonstrates continued momentum. PEG of 0.76 suggests the stock is reasonably priced for its growth.

Bull Case : CLOV

The strongest argument for CLOV centers on Revenue Growth. Revenue growth of 44.7% demonstrates continued momentum.

Bear Case : CI

The primary concerns for CI are Profit Margin, Operating Margin, Piotroski F-Score. Thin 2.2% margins leave little buffer for downturns.

Bear Case : CLOV

The primary concerns for CLOV are EPS Growth, Market Cap, Piotroski F-Score.

Key Dynamics to Monitor

CI profiles as a value stock while CLOV is a hypergrowth play — different risk/reward profiles.

CLOV carries more volatility with a beta of 2.24 — expect wider price swings.

CLOV is growing revenue faster at 44.7% — sustainability is the question.

CI generates stronger free cash flow (5.8B), providing more financial flexibility.

Bottom Line

CI scores higher overall (63/100 vs 36/100) and 10.4% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cigna Corp

HEALTHCARE · HEALTHCARE PLANS · USA

Cigna is an American multinational managed healthcare and insurance company based in Bloomfield, Connecticut. Its insurance subsidiaries are major providers of medical, dental, disability, life and accident insurance and related products and services, the majority of which are offered through employers and other groups (e.g. governmental and non-governmental organizations, unions and associations).

Visit Website →

Clover Health Investments Corp

HEALTHCARE · HEALTHCARE PLANS · USA

Clover Health Investments, Corp. The company is headquartered in Franklin, Tennessee.

Visit Website →

Want to dig deeper into these stocks?